ECRI Announces the 2024 Healthcare Supply Chain Excellence Award Winners PLYMOUTH MEETING, Pa., Sept. 27, 2024 /PRNewswire/ — ECRI, a global patient safety nonprofit organization, announced the winners of its 2024 Healthcare Supply Chain Excellence Award. ECRI’s annual award recognizes U….
Month: September 2024
AT&T Declares Dividends on Common and Preferred Shares
DALLAS, Sept. 27, 2024 /PRNewswire/ — The board of directors today declared a quarterly dividend of $0.2775 per share on the company’s common shares, payable November 1, 2024. Key Takeaways: The board of directors declared a quarterly dividend of $0.2775 per share on the company’s common…
AT&T Declares Dividends on Common and Preferred Shares
DALLAS, Sept. 27, 2024 /PRNewswire/ — The board of directors today declared a quarterly dividend of $0.2775 per share on the company’s common shares, payable November 1, 2024. Key Takeaways: The board of directors declared a quarterly dividend of $0.2775 per share on the company’s common…
DonutNV Launches “Sleigh The Holiday” Giveaway for Corporate Events
Win a FREE DonutNV Truck Visit for Your Corporate Holiday Event! ORLANDO, Fla., Sept. 27, 2024 /PRNewswire/ — DonutNV, the beloved mobile food trucks serving hot, fresh mini donuts and refreshing lemonade and iced coffee, is excited to announce the launch of its “Sleigh The Holiday”…
DonutNV Launches “Sleigh The Holiday” Giveaway for Corporate Events
Win a FREE DonutNV Truck Visit for Your Corporate Holiday Event! ORLANDO, Fla., Sept. 27, 2024 /PRNewswire/ — DonutNV, the beloved mobile food trucks serving hot, fresh mini donuts and refreshing lemonade and iced coffee, is excited to announce the launch of its “Sleigh The Holiday”…
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ — Johnson &…
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ — Johnson &…
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no…
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no…
USCF ANNOUNCES CHANGES TO PRODUCT LINE
WALNUT CREEK, Calif., Sept. 27, 2024 /PRNewswire/ — USCF, a leading-edge provider of exchange traded product innovation, announced today that it plans to close and liquidate one of its products as a result of a decision and vote by the Board of Trustees of USCF ETF Trust that approved…
